- Ascentage Pharma (NASDAQ: AAPG) to present clinical study data at 2025 ASCO Annual Meeting.
- Key focus on investigational drugs lisaftoclax (APG-2575) and alrizomadlin (APG-115).
- Presentations scheduled from May 30 to June 3, 2025, at McCormick Place, Chicago.
Ascentage Pharma (NASDAQ: AAPG), a biopharmaceutical firm specializing in therapies for hematological malignancies, announced it will present findings from two pivotal clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This major event will occur both online and in-person at McCormick Place, Chicago, from May 30 to June 3, 2025.
The company will deliver an oral presentation revealing updated data from a Phase Ib/II study of lisaftoclax (APG-2575), combined with azacitidine, targeting patients with treatment-naïve or venetoclax-exposed myeloid malignancies. This session is scheduled for June 2, 2025, from 3:00 PM to 6:00 PM Central Time.
Additionally, a poster presentation will discuss results from a Phase 2 trial of the MDM2 inhibitor alrizomadlin (APG-115), with or without toripalimab, in patients with advanced adenoid cystic carcinoma (ACC) and other solid tumors. This presentation is set for June 2, 2025, from 9:00 AM to 12:00 PM Central Time.
This marks the eighth consecutive year Ascentage Pharma has participated in the ASCO Annual Meeting, underscoring its ongoing commitment to advancing oncology research and developing innovative cancer therapies. Chief Medical Officer Dr. Yifan Zhai stated, "We are honored to return to the ASCO Annual Meeting to present the latest data on our novel assets and highlight our clinical development capabilities."
